IF 2.9 4区医学

Internist Pub Date : 2024-03-01 Epub Date: 2023-06-26 DOI: 10.1177/10600280231181135

Kimberly N Day, Julie A Vircks, Christine E Henricks, Kaci M Reaves, Ashley K Holmes, Karen L Florio

{"title":"Latency Antibiotics in Preterm Prelabor Rupture of Membranes: A Comparison of Azithromycin Regimens.","authors":"Kimberly N Day, Julie A Vircks, Christine E Henricks, Kaci M Reaves, Ashley K Holmes, Karen L Florio","doi":"10.1177/10600280231181135","DOIUrl":"10.1177/10600280231181135","url":null,"abstract":"Background: Treatment with antibiotics at the time of preterm prelabor rupture of membranes (PPROM) has been shown to prolong pregnancy. Due to the recurrent shortage of erythromycin, azithromycin has been substituted in the traditional regimen; however, there are little data on optimal dosing.Objective: The objective of this study was to determine whether there is a difference in latency from onset of PPROM to delivery in patients who received a single dose of azithromycin compared with a 5-day course.Methods: This was a single-center, multisite, retrospective, IRB approved analysis of patients admitted with a diagnosis of PPROM. Patients were included if rupture occurred between 22 0/7 and 33 6/7 weeks of gestation and received either a single dose or a 5-day course of azithromycin along with a beta lactam.Results: A total of 376 patients were reviewed with 296 patients included in the final analysis. There was no statistical difference in the primary outcome of latency days in patients who received the 5-day versus the single-dose course (4 vs 5 days, P = 0.641). There was a significantly higher rate of histologic chorioamnionitis in the single-dose course of azithromycin (46.4% vs 62.6%, P = 0.006).Conclusions and relevance: There was no difference in latency for patients who received a 5-day course of azithromycin versus a single dose for the treatment of PPROM. A higher rate of histologic chorioamnionitis was observed in those who received the single-day course. Prospective follow-up studies are needed to confirm these findings.","PeriodicalId":54924,"journal":{"name":"Internist","volume":"46 1","pages":"234-240"},"PeriodicalIF":2.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73518732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitteilungen des BDI BDI通信

4区医学

Internist Pub Date : 2022-08-23 DOI: 10.1007/s00108-022-01393-x

Berlin

引用次数: 0

Oberflächliche Venenthrombose, Varikose und chronische Veneninsuffizienz 局部静脉血栓，变种，以及慢性静脉注射功能

4区医学

Internist Pub Date : 2022-05-03 DOI: 10.1007/s00108-022-01341-9

M. Stücker

引用次数: 2

[Antibody therapy in patients with COVID-19]. [新冠肺炎患者的抗体治疗]。

4区医学

Internist Pub Date : 2022-05-01 Epub Date: 2022-04-04 DOI: 10.1007/s00108-022-01321-z

M Augustin, M Hallek, S Nitschmann

引用次数: 0

[Innovations in the pharmaceutical treatment of systemic lupus erythematosus]. 系统性红斑狼疮药物治疗的创新

4区医学

Internist Pub Date : 2022-05-01 Epub Date: 2022-01-20 DOI: 10.1007/s00108-021-01250-3

Johanna Mucke, Matthias Schneider

{"title":"[Innovations in the pharmaceutical treatment of systemic lupus erythematosus].","authors":"Johanna Mucke, Matthias Schneider","doi":"10.1007/s00108-021-01250-3","DOIUrl":"https://doi.org/10.1007/s00108-021-01250-3","url":null,"abstract":"Background: Systemic lupus erythematosus (SLE) is a heterogeneous disease with a complex pathogenesis. Until now, the choice of therapeutic agents has been limited.Objective: This review revisits known forms of treatment for SLE and introduces new recently approved agents and agents currently under investigation in clinical trials. The aim of this article is to map the current data from phase 2 and phase 3 studies and European recommendations for the management of SLE and to provide an outlook on the future of lupus treatment.Data situation: As the focus of SLE treatment is on the achievement of remission with low steroid dosages, early and effective immunosuppressive therapy is essential. With the interferon type I receptor antagonist anifroluma, a treatment for extrarenal lupus has been approved for the first time since 2011. For lupus nephritis, the well-known belimumab (approval by the U.S. Food and Drug Administration, FDA and the European Medicines Agency, EMA) and the calcineurin inhibitor voclosporin (FDA) are newly available. In addition, a large number of substances are currently undergoing clinical trials, e.g. the CD-20 inhibitor obinutuzumab, Janus kinase inhibitors and low-dose interleukin‑2.Conclusion: New and innovative treatment concepts are finding their way into lupus treatment and other promising substances are in the pipeline; however, only long-term data will show to what extent these improve the long-term outcome of patients. Nevertheless, these are important and much needed advances in the treatment of SLE.","PeriodicalId":54924,"journal":{"name":"Internist","volume":" ","pages":"566-572"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39845519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Spontaneous expulsion of a mesenchymal colonic tumor via the rectum]. [结肠间充质肿瘤经直肠自发排出]。

4区医学

Internist Pub Date : 2022-05-01 Epub Date: 2022-02-16 DOI: 10.1007/s00108-022-01278-z

Wolfgang Scheppach, Ulrich Steger, Wolfgang Küsters, Vanessa Wild

引用次数: 0

[Uncommon tumor-associated deep vein thrombosis]. [罕见的肿瘤相关深静脉血栓]。

4区医学

Internist Pub Date : 2022-05-01 Epub Date: 2022-02-23 DOI: 10.1007/s00108-022-01272-5

Rosemary Poulose, Anselm A Derda, Mohamed Omar, Christian von Falck, Florian Länger, Jochen Tillmanns, Adrian Groh, Johann Bauersachs, L Christian Napp

引用次数: 1

[Advance Care Planning-further development of the patient advance directive : What the specialist in internal medicine must know]. [预先护理计划-进一步发展病人预先指示:内科专家必须知道的事情]。

4区医学

Internist Pub Date : 2022-05-01 DOI: 10.1007/s00108-022-01333-9

S Petri, B Zwißler, J In der Schmitten, B Feddersen

{"title":"[Advance Care Planning-further development of the patient advance directive : What the specialist in internal medicine must know].","authors":"S Petri, B Zwißler, J In der Schmitten, B Feddersen","doi":"10.1007/s00108-022-01333-9","DOIUrl":"https://doi.org/10.1007/s00108-022-01333-9","url":null,"abstract":"Despite the availability of the instruments of advance directives, power of attorney and healthcare proxy, the patient's preferences for life-sustaining medical treatment in a specific situation often remain unknown. The aim of the systemically designed German Advance Care Planning (ACP) program is the reflection, documentation and implementation of patients' preferences regarding future medical treatment in case they are incapable of legally binding decision-making. A specially trained ACP facilitator initially supports the verbalization of the attitudes towards life, severe illness and death on an individual level. Based on these principal views, concrete preferences on how to be treated under defined medical circumstances can be discussed and documented in an advance directive. This includes the three scenarios medical emergency, inpatient hospital treatment in situations with decisional incapability of unknown duration and the situation of permanent cognitive impairment. Through cautious, nondirective conversational techniques in the sense of shared decision-making, the person is enabled to reflect and decide well-informed according to the informed consent standard. All persons participating in decisions regarding future medical treatment, especially future surrogate decision makers, are involved in the process as early as possible. A systematic institutional and regional implementation of the concept is necessary to ensure that the carefully assessed and documented preferences of the patients will be known and honored. The new German § 132g of the Social Code Book V (SGB V) enables institutions for long-term care and for the care of disabled persons, to offer facilitated ACP to all residents at the expense of the statutory health insurance funds. An increased dissemination of this concept is to be expected.","PeriodicalId":54924,"journal":{"name":"Internist","volume":"63 5","pages":"533-544"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Mitteilungen der DGIM DGIM的消息

4区医学

Internist Pub Date : 2022-04-28 DOI: 10.1007/s11377-013-0868-x

引用次数: 0

Sarkoidose und Berylliose 石棺和绿柱石

4区医学

Internist Pub Date : 2022-04-09 DOI: 10.1007/s00108-022-01323-x

Daniel Soriano, Caroline Quartucci, P. Agarwal, J. Müller-Quernheim, B. C. Frye

引用次数: 0

Internist最新文献